Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
NCT00344500 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122
Last updated 2016-04-06
Summary
This program aims to help Veterans who take antipsychotic medications lose weight. The investigators use a program based on the American Diabetes Association's "Diabetes Prevention Program," and the investigators have modified it to fit the lifestyles of people with mental illness. All participants are educated about nutrition and cutting down fat intake, how and when to exercise, and the causes of diabetes and how to prevent it. Participants must be Veterans who live within one hour of the West Los Angeles VA hospital.
Conditions
Interventions
- BEHAVIORAL
-
Behavioral Weight Loss Program
Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient * Be given a 7% weight loss goal * Be assisted in obtaining a 500 calorie reduction per day * Exercise for at least 30 min/day, at least 5 days a week * Maintain weekly food and exercise diaries * Be quizzed on their knowledge of healthy eating habits and nutrition
Sponsors & Collaborators
-
VA Office of Research and Development
lead FED
Principal Investigators
-
Donna Ames, MD · VA Greater Los Angeles Healthcare System, West Los Angeles, CA
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-10-31
- Primary Completion
- 2009-09-30
- Completion
- 2009-09-30
Countries
- United States
Study Locations
More Related Trials
-
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
NCT00790517 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
NCT00451399 ·Status: COMPLETED ·Phase: PHASE4
-
Anti-psychotic Medication (New Use) Weight Loss Study
NCT01272752 ·Status: WITHDRAWN ·Phase: PHASE2
-
Anti-psychotic Medication (Stable Dose) Weight Loss Study
NCT01272765 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
NCT00552500 ·Status: COMPLETED ·Phase: NA
-
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723 ·Status: COMPLETED ·Phase: NA
-
Improving Cardiometabolic Health of Youth on Antipsychotic Medication
NCT02877823 ·Status: COMPLETED ·Phase: NA
-
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
NCT00167934 ·Status: COMPLETED ·Phase: NA
-
Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragmatic Trial
NCT07342764 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Alleviating the Metabolic Side Effects of Antipsychotic Medications
NCT01567124 ·Status: WITHDRAWN ·Phase: PHASE4
-
Metabolic Effects of Antipsychotics in Children
NCT00205699 ·Status: COMPLETED ·Phase: PHASE4
-
Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.
NCT00759993 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
NCT01794429 ·Status: COMPLETED ·Phase: PHASE3
-
Antipsychotic Medicine and Metabolic Syndrome
NCT00627757 ·Status: UNKNOWN
-
β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS
NCT00528359 ·Status: COMPLETED
-
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
NCT00806234 ·Status: COMPLETED ·Phase: PHASE4
-
MetSense Pilot and Feasibility
NCT07264062 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
NCT00617240 ·Status: COMPLETED ·Phase: PHASE2
-
Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?
NCT01845259 ·Status: UNKNOWN ·Phase: PHASE2
-
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
NCT00794963 ·Status: TERMINATED ·Phase: NA
-
Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine
NCT00617058 ·Status: TERMINATED ·Phase: PHASE2
-
Psychosis and Type 2 Diabetes Study (PODS)
NCT05496907 ·Status: UNKNOWN ·Phase: NA
-
Metformin for Weight Loss in Schizophrenia
NCT01177709 ·Status: TERMINATED ·Phase: NA
-
Metformin for Treatment of Antipsychotic-induced Dyslipidemia
NCT01778244 ·Status: COMPLETED ·Phase: PHASE4
-
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
NCT04892199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4